Agilent Technologies ($NYSE:A) recently reported their fiscal fourth quarter earnings, and they shocked the analysts by beating expectations. Their Non-GAAP EPS of $1.38 exceeded expectations by $0.04, while revenue of $1.69B was higher than anticipated by $10M. This jump in earnings and revenue has been attributed to strong performances across all of Agilent’s business segments. Agilent Technologies is a leading global provider of instruments, software, services and consumables for chemical analysis, life sciences, diagnostics, and other markets in the laboratory space. They are a publicly traded company on the New York Stock Exchange and have a market capitalization of over $20 billion.
In recent times, they have been investing in new technologies such as artificial intelligence and analytics, which could be a major part of their future success. Overall, investors were delighted with Agilent Technologies’ performance in the fourth quarter as it further solidified their position as one of the top players in the laboratory industry. By continuing to innovate and invest in new technologies, they should be well-positioned to remain successful in the years to come.
AGILENT TECHNOLOGIES has reported its earnings for the third quarter of FY2023 with total revenue of 1586.0M USD and a net income of 264.0M USD, which beats the estimates. While compared to the same period last year, there is a 7.7% decrease in total revenue and a 19.8% decrease in net income. Despite this, AGILENT TECHNOLOGIES has seen a steady increase in total revenue over the last three years, reaching 1672.0M USD at the end of this quarter.
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Agilent Technologies. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Agilent Technologies. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Agilent Technologies. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Agilent Technologies are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Monday was a positive day for AGILENT TECHNOLOGIES as their stock opened at $113.2 and closed at $114.0, up 0.7% from the prior closing price. This was due to the company’s better-than-expected earnings and revenue report. Live Quote…
Analysis – Agilent Technologies Intrinsic Value Calculator
At GoodWhale, we conducted an analysis of AGILENT TECHNOLOGIES‘s wellbeing and our proprietary Valuation Line has calculated the fair value of AGILENT TECHNOLOGIES share to be around $148.2. Currently, AGILENT TECHNOLOGIES stock is traded at $114.0, which means it is undervalued by 23.1%. This indicates that there are opportunities to gain value from the current market price. More…
Star Chart Analysis
The company has a strong presence in the market and competes with Qiagen NV, Thermo Fisher Scientific Inc, Illumina Inc, and other companies. Agilent Technologies Inc. is committed to providing innovative products and services that meet the needs of customers and enable them to achieve their research goals.
Qiagen is a Dutch company that provides molecular diagnostic solutions, including kits and instruments for sample preparation and real-time PCR. The company has a market cap of 9.99B as of 2022 and a ROE of 13.07%.
– Thermo Fisher Scientific Inc ($NYSE:TMO)
Thermo Fisher Scientific Inc is a biotechnology company that manufactures and sells scientific instruments, reagents, and laboratory products. The company has a market capitalization of 201.37 billion as of 2022 and a return on equity of 12.43%. Thermo Fisher Scientific is a global leader in serving science, with revenues of more than $30 billion and a workforce of more than 70,000 employees. The company’s mission is to enable its customers to make the world healthier, cleaner, and safer.
Illumina Inc. is an American company headquartered in San Diego, California. It is a provider of sequencing and array-based solutions for genetic analysis. The company has a market cap of $36.65 billion as of 2022 and a return on equity of 0.28%. Illumina’s products are used by academic and commercial researchers in a variety of fields, including cancer, infectious disease, genetics, and more.
Revenue of $1.69 billion also surpassed estimates by $10 million. This marks the third consecutive quarter of year-over-year growth for Agilent Technologies, indicating that the company is successfully navigating the current economic environment. The strong results were driven by a robust performance across the company’s product segments, including diagnostic and genomics, life sciences, and chemical and energy.
Additionally, strong demand for its services and solutions offerings, as well as successful cost-saving initiatives, contributed to the strong performance. Investors should look for further positive developments from Agilent Technologies in upcoming quarters in order to maintain its trend of healthy growth.